Treatment of BRL 28500 (clavulanic acid-ticarcillin) for infections in patients with hematological diseases

Keisuke Toyama, Shinichiro Okamoto, Hiroshi Uchida, Yasuhiko Ando

研究成果: Article査読

抄録

BRL 28500, ticarcillin combined with clavulanic acid, was evaluated clinically for infections in 5 patients with hematological diseases. BRL 28500 was administrated by one-hour drip intravenous infusion at a daily dose of 12.8g for 4 to 10 days. Duration of BRL 28500 therapy was determined according to the patient's condition. Five cases consisted of 2 cases with possible septicemia, 2 cases with pneumonia and/or possible septicemia and one with cellulitis. The clinical response to BRL 28500 therapy of possible septicemia was good in one case, but all other cases did not respond to BRL 28500. No significant side effect was observed after the administration of BRL 28500.

本文言語English
ページ(範囲)452-454
ページ数3
ジャーナルCHEMOTHERAPY
34
DOI
出版ステータスPublished - 1986 1月 1

ASJC Scopus subject areas

  • 薬理学(医学)
  • 感染症
  • 薬理学
  • 創薬
  • 腫瘍学

フィンガープリント

「Treatment of BRL 28500 (clavulanic acid-ticarcillin) for infections in patients with hematological diseases」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル